There are currently 14 active clinical trials seeking participants for NASH - Nonalcoholic Steatohepatitis research studies. The states with the highest number of trials for NASH - Nonalcoholic Steatohepatitis participants are Texas, Florida, California and Arizona.
Tocotrienol Against the Progression of End Stage Liver Disease
NCT02581085
Recruiting
The purpose of this Phase 2 trial is to validate the outcome observed in a previous trial that oral Tocotrienol (TCT) attenuates the rise in MELD score over time in patients with end stage liver disease / cirrhosis. The study is double blind and participants will be randomized to take 2 capsules of TCT (200mg) or placebo twice a day for 3 years.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/19/2023
Locations: IU Health Unviersity Hospital, Indianapolis, Indiana
Conditions: End Stage Liver Disease, NASH - Nonalcoholic Steatohepatitis, NAFLD - Nonalcoholic Fatty Liver Disease
Register for Updates
Estrogen Administration for the Treatment of NASH in Postmenopausal Women
NCT04833140
Recruiting
Non-alcoholic fatty liver disease (NAFLD) is a growing epidemic in the United States. Despite this, the treatment options remain limited. Preclinical and preliminary clinical data suggest that estrogen deficiency plays an important role in the pathology of steatosis, inflammation and fibrosis in non-alcoholic steatohepatitis (NASH), the progressive form of NAFLD. Post-menopausal women are a growing population with particularly high risk of NASH due to their lack of estrogen. This study will exam... Read More
Gender:
Female
Ages:
Between 45 years and 70 years
Trial Updated:
04/07/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates